InflaRx Receives Nasdaq Deficiency Notice Over Minimum Bid Price

InflaRx, a clinical-stage biopharmaceutical company, received a Nasdaq deficiency notice due to its minimum bid price below $1. The company focuses on developing monoclonal antibodies for inflammatory diseases. Its lead product, IFX-1, is in Phase II trials for Hidradenitis Suppurativa and ANCA-associated vasculitis, while IFX-2 is in preclinical development. InflaRx must regain compliance with Nasdaq's listing requirements within 180 days.

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company specializing in anti-inflammatory therapeutics, has received a Nasdaq deficiency notice on July 11, 2025. The notice indicates that the company's common shares have closed below the minimum bid price requirement of $1.00 per share for the last 30 consecutive business days, as per Nasdaq Listing Rule 5450(a)(1) [1].

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), InflaRx has been granted an initial period of 180 calendar days, or until January 7, 2026, to regain compliance [1]. If the company fails to meet the minimum bid price requirement within this period, it may consider transferring its securities from the Nasdaq Global Select Market to the Nasdaq Capital Market. This transfer could provide an additional 180 days, or until July 6, 2026, to regain compliance, provided that InflaRx meets the applicable market value of publicly held shares and other listing requirements [1].

InflaRx's lead product, vilobelimab, is currently in Phase II trials for Hidradenitis Suppurativa and ANCA-associated vasculitis, while IFX-2 is in preclinical development. The company's focus on developing monoclonal antibodies for inflammatory diseases underscores its potential in the biopharmaceutical sector [1].

The Nasdaq deficiency notice has no immediate effect on InflaRx's listing status or the trading of its shares. The company intends to monitor the bid price of its common shares and consider available options to regain compliance with the Minimum Bid Price Rule [1].

References:
[1] https://www.morningstar.com/news/globe-newswire/9493299/inflarx-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement